Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia.

J. Randolph Hecht, Charles D. Blanke, A. B. Benson, Heinz J. Lenz

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Both irinotecan (CPT-11, Camptosar) and paclitaxel have been shown to have single-agent activity in adenocarcinomas of the esophagus and gastric cardia. A phase I trial of the combination at UCLA established the dose as irinotecan at 225 mg/m2 and paclitaxel at 100 mg/m2 every 3 weeks. Preliminary data from a phase II trial of this regimen in adenocarcinomas of the gastroesophageal junction show good tolerability and promising activity (response rate of 27%), even in previously treated patients.

Original languageEnglish (US)
Pages (from-to)13-15
Number of pages3
JournalOncology (Williston Park, N.Y.)
Volume17
Issue number9 Suppl 8
StatePublished - Sep 2003

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia.'. Together they form a unique fingerprint.

  • Cite this